COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,044 Articles (22,627 medRxiv, 8,417 bioRxiv)

Most recent first Previous |  Page 579: Articles 5781-5790  | Next

Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers
Schmidt, P., Narayan, K., Li, Y., Kaku, C., Brown, M., Champney, E., Geoghegan, J., Vasquez, M., Krauland, E., Yockachonis, T., Bai, S., Gunn, B., Cammarata, A., Rubino, C., Walker, L. M.
10.1101/2022.10.18.22281172 — Posted: 2022-10-19
Infection of primary nasal epithelial cells differentiates among lethal and seasonal human coronaviruses
Otter, C., Fausto, A., Tan, L. H., Cohen, N. A., Weiss, S. R.
10.1101/2022.10.17.512617 — Posted: 2022-10-18
Deep learning-based Drug discovery of Mac domain of SARS-CoV-2 (WT) Spike inhibitors: using experimental ACE2 Inhibition TR-FRET Assay Screening and Molecular Dynamic Simulations.
Iqbal, S., Lin, S. X.
10.1101/2022.10.17.512637 — Posted: 2022-10-18
N6-Adenosine Methylation of SARS-CoV-2 5-UTR Regulates Translation
Aly, A., Scott, G., Calderon, M., Haghighi, P.
10.1101/2022.10.17.512569 — Posted: 2022-10-18
SARS-CoV-2 vaccine and increased myocarditis mortality risk: A population based comparative study in Japan
Watanabe, S., Hama, R.
10.1101/2022.10.13.22281036 — Posted: 2022-10-18
Viral infectivity in pediatric SARS-CoV-2 clinical samples does not vary by age
Schmidt, M. M., Despres, H. W., Shirley, D. J., Bose, M. E., McCaul, K. C., Crothers, J. W., Henrickson, K. J., Lee, B., Bruce, E. A.
10.1101/2022.10.17.22281193 — Posted: 2022-10-18
Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial
McCarthy, M. W., Naggie, S., Boulware, D. R., Lindsell, C. J., Stewart, T. G., Felker, G. M., Jayaweera, D., Sulkowski, M., Gentile, N., Bramante, C., Singh, U., Dolor, R. J., Ruiz-Unger, J., Wilson, S., DeLong, A., Remaly, A., Wilder, R., Collins, S., Dunsmore, S. E., Adam, S. J., Thicklin, F., Hanna, G., Ginde, A. A., Castro, M., McTigue, K., Shenkman, E., Hernandez, A. F.
10.1101/2022.10.17.22281178 — Posted: 2022-10-18
Determinants and Mechanisms of the Low Fusogenicity and Endosomal Entry of Omicron Subvariants
Qu, P., Evans, J. P., Kurhade, C., Zeng, C., Zheng, Y.-M., Xu, K., Shi, P.-Y., Xie, X., Liu, S.-L.
10.1101/2022.10.15.512322 — Posted: 2022-10-17
The Impact of Protein Dynamics on Residue-Residue Coevolution and Contact Prediction
Fung, A., Koehl, A., Jagota, M., Song, Y. S.
10.1101/2022.10.16.512436 — Posted: 2022-10-17
Comparative Mutagenesis of SARS-CoV-2 Nonstructural Proteins (NSPs) Across Variants: The Case for RdRp as a Therapeutic Target
Lanclos, N.
10.1101/2022.10.15.512346 — Posted: 2022-10-17

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).